BerGenBio

Regulatory Filings • May 25, 2023

BerGenBio Announces Abstracts Accepted for Presentation at 2023 ASCO

BerGenBio Announces Abstracts Accepted for Presentation at 2023 ASCO

- Oral presentation to reveal data from trial evaluating bemcentinib in relapsed

mesothelioma -

- Trial-in-Progress poster to be presented regarding the BGBC016 1L STK11m NSCLC

trial -

BERGEN, Norway, May 25, 2023 - BerGenBio ASA (OSE: BGBIO), a clinical-stage

biopharmaceutical company developing novel, selective AXL kinase inhibitors for

severe unmet medical needs, today announced that the Company will be presenting

two abstracts at the 2023 American Society of Clinical Oncology (ASCO) Annual

Meeting in Chicago June 2-6, 2023.

An oral presentation will highlight the results of MIST3, an investigator led,

multi-center Phase IIa study led by Professor Dean Fennell at the University of

Leicester, UK that assessed the use of bemcentinib in combination with

pembrolizumab in patients with relapsed mesothelioma.

A Trial-in-Progress poster will outline the plans for the ongoing BGBC016 Phase

1b/2a study evaluating bemcentinib in combination with pembrolizumab and

chemotherapy in 1L STK11m NSCLC patients.

The abstracts will be available in Scientific

Presentations (https://www.bergenbio.com/investors/presentations/) on the

Company's website shortly after their presentations at the conference.

ASCO Abstract Details:

Oral Presentation

Title: Bemcentinib and pembrolizumab in patients with relapsed mesothelioma:

MIST3, a phase IIa trial with cellular and molecular correlates of

efficacy (https://meetings.asco.org/abstracts-presentations/222514)

Abstract Number: 8511

Abstract Session: Lung Cancer

Presenter: Matthew Krebs, Ph.D., FRCP, Christie Hospital, Manchester, UK

Date/Time: Monday 5th June, 11.30am - 1.00pm

Poster Presentation

Title: Phase 1b/2a safety and tolerability study of bemcentinib (BEM) with

pembrolizumab/carboplatin/pemetrexed in first line (1L) advanced or metastatic

non-squamous non-small cell lung cancer (NSCLC) without/with a STK11

mutation (https://meetings.asco.org/abstracts-presentations/226055)

Abstract Number: TPS9154

Poster Number: 134b

Abstract Session: Lung Cancer - Non-Small Cell Metastatic

Presenter: Rajwanth Veluswamy, MD, MSCR, Mount Sinai, New York, NY

Date/Time: Sunday 4th June 8.00am-11.00am

-End-

Contacts

Martin Olin CEO, BerGenBio ASA

ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA

rune.skeie@bergenbio.com

Investor Relations

Graham Morrell

graham.morrell@bergenbio.com

Media Relations

Jan Lilleby

jl@lillebyfrisch.no

+47 90 55 16 98

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing

transformative drugs targeting AXL as a potential cornerstone of therapy for

aggressive diseases, including cancer and severe respiratory infections. The

Company is focused on its proprietary lead candidate, bemcentinib, a potentially

first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC

and severe respiratory infections.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The

company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more

information, visit?www.bergenbio.com

Forward looking statements

This announcement may contain forward-looking statements, which as such are not

historical facts, but are based upon various assumptions, many of which are

based, in turn, upon further assumptions. These assumptions are inherently

subject to significant known and unknown risks, uncertainties, and other

important factors. Such risks, uncertainties, contingencies and other important

factors could cause actual events to differ materially from the expectations

expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5

-12 of the Norwegian Securities Trading Act.